Febuxostat

M04AA

Revideret: 23.08.2021

Præparater

Indholdsstof Navn og firma Dispform og styrke Pakning Pris enh. Pris DDD
Febuxostat Adenuric
PharmaPrim
filmovertrukne tabletter  80 mg 28 stk. (blister)   5,89 5,89
Febuxostat Adenuric
PharmaPrim
filmovertrukne tabletter  80 mg 84 stk. (blister)   5,92 5,92
Febuxostat Adenuric
PharmaPrim
filmovertrukne tabletter  120 mg 28 stk. (blister)   5,80 3,87
Febuxostat Febuxostat "Accord"
Accord
filmovertrukne tabletter  80 mg 28 stk. (blister)   5,13 5,13
Febuxostat Febuxostat "Accord"
Accord
filmovertrukne tabletter  80 mg 84 stk. (blister)   5,84 5,84
Febuxostat Febuxostat "Accord"
Accord
filmovertrukne tabletter  120 mg 28 stk. (blister)   2,84 1,89
Febuxostat Febuxostat "Krka"
KRKA
filmovertrukne tabletter  80 mg 28 stk. (blister)   5,37 5,37
Febuxostat Febuxostat "Medical Valley"
Medical Valley
filmovertrukne tabletter  80 mg 28 stk. (blister)   3,07 3,07
Febuxostat Febuxostat "Medical Valley"
Medical Valley
filmovertrukne tabletter  120 mg 28 stk. (blister)   2,94 1,96
Febuxostat Febuxostat "Teva"
TEVA
filmovertrukne tabletter  80 mg 28 stk. (blister)   3,02 3,02
Febuxostat Febuxostat "Teva"
TEVA
filmovertrukne tabletter  120 mg 28 stk. (blister)   2,84 1,89

Referencer

5342. Mackenzie IS, Ford I, Nuki G et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396:1745-57, https://pubmed.ncbi.nlm.nih.gov/33181081/ (Lokaliseret 9. marts 2022)

 

5341. White WB, Saag KG, Becker MA et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018; 378:1200-10, https://pubmed.ncbi.nlm.nih.gov/29527974/ (Lokaliseret 9. marts 2022)

 

2001. Becker MA, Schumacher HR, Wortmann RL et al. Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. The New England Journal of Medicine. 2005; 353:2450-61, https://pubmed.ncbi.nlm.nih.gov/16339094/ (Lokaliseret 26. april 2023)

 
 
 
Gå til toppen af siden...